Main > NEUROLOGY. > Alzheimer's Disease > Beta Secretase [BACE1 (Abbrev.)] > Aspartyl Protease 2 (Asp2). > Inhibitor. > Identification Method. > Patent. > Claims Etc > Claim 1: Method Identifying Agent > Modulates Activity of Asp2 Aspartyl > Protease, Comprising the Steps: a) > Contacting Asp2 Aspartyl Protease > with APP in Presence & Absence of > Test Agent; Asp2 Aspartyl Protease > Recombinant Polypeptide Exhibits > Asp2 Aspartyl Protease Activity > Involved in Processing APP into > Amyloid Beta & Expressed by Host > Cell Transformed with Nucleic Acid > Molecule that Encodes Polypeptide > , Hybridizes at Following Stringent > Hybridization Conditions to > Complement of SEQ ID NO: 3: (1) > Hybridization at 42C; Buffer: > 6.times.SSC & 0.1% SDS. (2) Wash > at 65C in Soln.: 1.times.SSC & > 0.1% SDS; b) Determine APP > Processing Activity Asp2 Aspartyl > Protease in Presence & Absence of > Test Agent & c) Identify Test Agent > as Inhibitor if Protease Activity > is Decreased in Pres. Test Agent. > Claim 2: Human Isoform of APP. > Claim 3: APP Beta-Secretase Cleavag > e Site. Swedish Mutation > (K.fwdarw.N, M.fwdarw.L). Claim 4: > APP Carboxy-Terminal Di-Lysine (KK) > Claim 5: APP Expressed in Byte Cell

---

Claim 5: APP Expressed in Byte Cell's subsections
Claim 6: Method Identifying Agent

Claim 5: APP Expressed in Byte Cell's products
This section has no products